|View printer-friendly version|
|May 23, 2014 8:00 a.m.|
|Teva Received FDA Approval for QVAR® (beclomethasone dipropionate HFA) with Dose Counter|
All Teva Respiratory Brands in
“Bringing QVAR® with a dose counter to market reaffirms
Teva’s commitment to addressing unmet needs by providing high-quality
and innovative solutions to patients,” said
QVAR® is an inhaled corticosteroid (ICS) recommended as a twice-daily treatment for long-term asthma control. Adherence to daily control medications, like QVAR®, is important because when asthma is well controlled, fewer asthma attacks may occur.
“Inhaled corticosteroid treatments, like QVAR®, should be
taken daily by patients with mild-to-moderate persistent asthma to
reduce inflammation in the airways and prevent asthma symptoms,” said
Over the last decade, the Asthma and Allergy Network Mothers of Asthmatics (AANMA) has conducted several surveys that found patients with asthma do not have a reliable means of monitoring the contents of their metered-dose inhalers (MDIs) resulting in serious problems for many patients. Thus, AANMA recommends that all manufacturers should include dose counters as a standard feature of every metered-dose inhaler (MDI).
In 2003, the
QVAR® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR® is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR® may reduce or eliminate the need for systemic corticosteroids.
Important Safety Information
QVAR® does not replace quick-relief inhalers for sudden symptoms.
CAUTION: If you are stopping or switching from an oral corticosteroid to QVAR®, follow your doctor's instructions to avoid health risks.
Inhaled corticosteroids may cause a reduction in growth rate, so children taking QVAR® should have their growth checked regularly. The long-term effect on final adult growth is unknown.
Do not stop taking QVAR® abruptly without talking to your doctor.
In clinical studies, common side effects included headache and sore throat. These are not all of the possible side effects of QVAR®. For more information, ask your healthcare provider or pharmacist.
You are encouraged to report negative side effects of prescription drugs
For full Prescribing Information, please click here:
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our innovative products, especially COPAXONE®
(including competition from orally-administered alternatives, as well as
from potential purported generic equivalents); the possibility of
material fines, penalties and other sanctions and other adverse
consequences arising out of our ongoing FCPA investigations and related
matters; our ability to achieve expected results from the research and
development efforts invested in our pipeline of specialty and other
products; our ability to reduce operating expenses to the extent and
during the timeframe intended by our cost reduction program; our ability
to identify and successfully bid for suitable acquisition targets or
licensing opportunities, or to consummate and integrate acquisitions;
the extent to which any manufacturing or quality control problems damage
our reputation for quality production and require costly remediation;
our potential exposure to product liability claims that are not covered
by insurance; increased government scrutiny in both the U.S. and